SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-19-026368
Filing Date
2019-10-30
Accepted
2019-10-30 19:53:29
Documents
2
Period of Report
2019-10-30

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3211
2 EX-24 DOCUMENT attachment1.htm EX-24 2376
  Complete submission text file 0000899243-19-026368.txt   7014
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Issuer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences

Mailing Address C/O ALIMERA SCIENCES, INC. 6120 WINDWARD PARKWAY, SUITE 290 ALPHARETTA GA 30005
Business Address
Snisarenko John (Reporting) CIK: 0001783264 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39112 | Film No.: 191181594